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Abstract
Objective: Mortality in patients with primary adrenal insufficiency (PAI) is significantly increased, with respiratory 
infections as a major cause of death. Moreover, patients with PAI report an increased rate of non-fatal infections. 
Neutrophils and natural killer (NK) cells are innate immune cells that provide frontline protection against invading 
pathogens. Thus, we compared the function and phenotype of NK cells and neutrophils isolated from PAI patients 
and healthy controls to ascertain whether altered innate immune responses could be a contributory factor for the 
increased susceptibility of PAI patients to infection. 
Design and methods: We undertook a cross-sectional study of 42 patients with PAI due to autoimmune adrenalitis 
(n = 37) or bilateral adrenalectomy (n = 5) and 58 sex- and age-matched controls. A comprehensive screen of innate 
immune function, consisting of measurements of neutrophil phagocytosis, reactive oxygen species production, NK cell 
cytotoxicity (NKCC) and NK cell surface receptor expression, was performed on all subjects.
Results: Neutrophil function did not differ between PAI and controls. However, NKCC was significantly reduced in PAI 
(12.0 ± 1.5% vs 21.1 ± 2.6%, P < 0.0001). Phenotypically, the percentage of NK cells expressing the activating receptors 
NKG2D and NKp46 was significantly lower in PAI, as was the surface density of NKG2D (all P < 0.0001). Intracellular 
granzyme B expression was significantly increased in NK cells from PAI patients (P < 0.01).
Conclusions: Adrenal insufficiency is associated with significantly decreased NKCC, thereby potentially compromising 
early recognition and elimination of virally infected cells. This potential impairment in anti-viral immune defense may 
contribute to the increased rate of respiratory infections and ultimately mortality in PAI. 
Introduction
Primary adrenal insufficiency (PAI), or Addison’s 
disease, is characterized by the insufficient production 
of mineralocorticoids, glucocorticoids and androgen 
precursors by the adrenal cortex. Daily corticosteroid 
replacement therapy is the standard treatment for 
adrenal failure, and since its introduction following the 
Nobel Prize-winning achievements of Kendall, Hench 
and Reichstein (1), the life expectancy of PAI patients 
has increased considerably (2, 3). However, despite ready 
availability of corticosteroid replacement, Addison’s 
patients not only suffer from a suboptimal quality of 
life (4, 5) but also from an increased risk of premature 
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death, with infections reported as a major cause (6, 7). 
A population-based, retrospective, observational study 
in patients with Addison’s disease (6) found a two-fold 
increased risk ratio for death and a five times higher 
mortality rate from infections than in the general 
population, with pneumonia being the major cause of 
infection-related death. In line with these observations, 
Erichsen  et  al. (7) subsequently reported an increased 
standard mortality rate (SMR) for PAI patients, with 
infections being the cause of death in 10% of these 
patients, compared to 6% in the general population. 
Infectious diseases have also been documented as a 
main cause of death in patients with secondary adrenal 
insufficiency due to hypopituitarism, when compared 
to hypopituitarism patients with normal hypothalamic–
pituitary–adrenal axis function (SMR 8.88) (8). 
Infection is an acute process that triggers a cytokine-
mediated inflammatory stress response including an 
increased requirement for glucocorticoid activity; 
therefore, in adrenal insufficiency, a superimposed adrenal 
crisis can contribute to the observed increase in mortality 
arising from infections. Indeed, most of adrenal crises 
are precipitated by an infection as the trigger, and in the 
majority of cases, underlying viral infections have been 
documented (3, 9). Patients with adrenal insufficiency 
have also been reported to suffer from an increased rate 
of non-fatal infections, with a 1.5-fold increased risk 
of use of anti-microbial agents and a 4.0- to 5.0-fold 
increased risk of hospital admission for infection (10), 
with rates of pneumonia reported to be more than nine 
times higher in adrenal insufficiency patients. However, 
despite these well-documented reports about increased 
incidence and severity of infection among PAI patients, 
it is currently unknown as to why these individuals 
succumb more readily to infections when compared to 
the general population.
Neutrophils and natural killer (NK) cells are critical 
effector cells of the innate immune system and serve as 
the first line of defense against viral, fungal and bacterial 
infections. We hypothesized that an impairment in 
the function of either or both of these major cell types 
underlies the increased susceptibility of PAI patients 
to infection. Neutrophils provide immediate frontline 
anti-microbial protection by phagocytosis of microbes 
and the generation of reactive oxygen species (ROS), 
whereas NK cell-mediated elimination of virus-infected 
cells is achieved primarily through contact-dependent 
cytotoxicity. Thus, the objective of this cross-sectional 
study was to examine the innate immune response in 
adrenal insufficiency. To this end, we analyzed both the 
function and surface phenotype of neutrophils and NK 
cells in a cohort of patients with PAI receiving chronic 
corticosteroid replacement in comparison to sex- and age-
matched healthy controls.
Subjects and methods
Subjects
We carried out a cross-sectional study with prospective 
enrolment of patients with an established diagnosis of 
PAI and sex- and age-matched healthy controls, with total 
recruitment taking place over a period of 18  months. 
Exclusion criteria were acute illness, immunological 
disease, significant comorbidities likely to influence 
immune function and intake of drugs that are known 
to affect steroid synthesis, metabolism or immunity. 
Subjects provided written informed consent prior to the 
enrolment and after the approval of the study protocol 
by the local research ethics committee. Blood samples 
were taken in the morning (09:00–11:30 h), which in the 
PAI patients equated to 2–5 h after intake of their regular 
morning glucocorticoid replacement dose. In addition to 
taking a detailed history during the study visit, medical 
records were reviewed to obtain clinical information.
Steroid hormone analysis
Steroids were extracted from 200 µL of serum by liquid/
liquid extraction using MTBE (tert-methyl butyl ether) 
as described previously (11). DHEA sulfate (DHEAS) was 
extracted from 20 µL of serum after protein precipitation 
as described by Chadwick et al. (12).
A Waters Xevo Mass Spectrometer with an electrospray 
ionization source (in positive ionization mode) and an 
attached Acquity liquid chromatography system was 
used to identify and quantify the steroids. Steroids were 
eluted using a HSS T3, 1.8 µm, 1.2 × 50 mm column using 
an optimized methanol/water 0.1% formic acid gradient 
system. After initial analysis, samples were evaporated 
and derivatized to form oxime derivatives to improve the 
sensitivity to DHEA. 
For accurate quantitation using liquid 
chromatography–tandem mass spectrometry, two mass 
transitions for each steroid analyte and its isotopically 
labeled internal standard were defined, followed by 
quantification facilitated by referring to a calibration 
series spanning the expected concentration range for 
unconjugated steroids, 0.25–500 ng/mL, and for DHEA 
sulfate (DHEAS), 0.25–10 µg/mL.
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Isolation of immune cells
Peripheral blood mononuclear cells (PBMCs) were isolated 
from whole blood by Ficoll density gradient centrifugation. 
NK cells were isolated from PBMCs by negative selection 
using magnetic assisted cell sorting (MACS) technology 
according to manufacturer’s instructions (Miltenyi Biotec, 
Gladbach, Germany). NK cells routinely constituted 
≥96% of the isolated cell population.
Assessment of neutrophil function and  
surface phenotype
Measurement of neutrophil phagocytosis and reactive 
oxygen species (ROS) production
Following manufacturer’s instructions of the 
commercially available PhagoTEST and PhagoBURST kits 
(BD Biosciences), neutrophil phagocytosis of opsonized 
Escherichia coli (E. coli) and ROS production in response 
to E. coli stimulation respectively, were measured in 
100 µL aliquots of heparinized whole blood. For both 
assays, 10 000 neutrophils were analyzed on an Accuri 
C6 flow cytometer and data were evaluated using CFlow 
software (BD Biosciences). Phagocytosis was recorded as 
the percentage of neutrophils that had phagocytosed 
bacteria and the number of bacteria engulfed per cell 
(mean fluorescent intensity (MFI)). Using both measures, 
the phagocytic index (PI) of neutrophils was calculated as 
(% of neutrophils that had ingested bacteria/100) × MFI. 
CD16 surface expression
100 µL aliquots of heparinized whole blood were 
immunostained for 20 min on ice with 4 µg/mL CD16-APC-
conjugated antibody (Clone 3G8; BD Biosciences) or its 
concentration-matched isotype control. After incubation, 
red blood cells were lysed (BD FACS Lyse solution, BD 
Biosciences), samples were washed in phosphate-buffered 
saline (PBS) and CD16 expression on 10 000 neutrophils 
was analyzed on an Accuri C6 flow cytometer.
Assessment of natural killer (NK) cell function and 
surface phenotype
Phenotypic analysis of PBMC samples
PBMCs (2 × 105) were immunostained on ice for 20 min 
with combinations of the following fluorochrome-
conjugated mouse monoclonal antibodies or their 
concentration-matched isotype controls: 1 µg/mL 
CD3-Pacific Blue (Clone UCHT1; BD Biosciences), 1 µg/mL 
CD3-PeCy7 (Clone UCHT1; eBioscience, Hatfield, UK), 
1 µg/mL CD56-PE (Clone AF12-7H3; Miltenyi Biotec), 
5 µg/mL NKp46-Pacific Blue (Clone 9E2; BioLegend, 
Cambridge, UK) or 10 µg/mL NKG2D-PeCy7 (Clone 1D11; 
BioLegend). After incubation, samples were washed in PBS 
prior to flow cytometric analysis on a CyANADP cytometer 
(Dako, Cambridgeshire, UK) where receptor expression 
was studied on 5000 CD3− CD56DIM NK cells.
Measurement of NK cell activating receptor expression 
on isolated NK cells
Resting NK cells (2 × 105) were immunostained for 20 min 
on ice with 5 µg/mL of purified mouse anti-human NKp30 
antibody (Clone P30-15; BioLegend) or its concentration-
matched isotype control (Clone MOPC-21; BioLegend). 
After a single wash in PBS, samples were resuspended in 
PBS/1% bovine serum albumin (BSA) containing 20% (vol/
vol) goat serum (Sigma-Aldrich) and incubated for 20 min 
on ice, after which cells were washed in PBS and pellets 
were resuspended in PBS/1%BSA containing 10 µg/mL of 
FITC goat anti-mouse IgG (Clone Poly4053; BioLegend). 
After a 20-min incubation on ice, cells were washed in PBS 
and analyzed on a CyANADP cytometer, where 10 000 NK 
cells were assessed. 
Intracellular staining for the assessment of perforin and 
granzyme B expression
Resting NK cells (2 × 105) were fixed for 30 min at 
room temperature (RT) in fixation medium (Life 
Technologies). After incubation, samples were washed 
in PBS and resuspended in permeabilization medium 
(Life Technologies) that contained 10 µg/mL of a FITC-
conjugated monoclonal antibody against human perforin 
(Clone δG9; BioLegend), 16 µg/mL of a FITC-conjugated 
monoclonal antibody against human granzyme B (Clone 
GB11; BioLegend) or their concentration-matched 
isotype controls. Samples were incubated for 30 min at RT 
and then washed in PBS prior to flow cytometric analysis, 
where on a CyANADP cytometer (Dako), 10 000 NK cells 
were studied.
NK cell cytotoxicity (NKCC) assay
NKCC was assessed using a modified version of the 
protocol described by Godoy-Ramirez et al. (13). Briefly, 
K562 target cells were cultured either alone or with 
NK cells at an effector:target (E:T) cell ratio of 10:1 for 
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4 h at 37°C in a humidified 5% CO2 atmosphere. After 
incubation, cells were pelleted and resuspended in 
PBS/1%BSA containing 0.3 µg anti-CD56 PE (Miltenyi 
Biotec). Following a 10-min incubation on ice, samples 
were washed in PBS and stained for 5 min with 125 nM of 
the dead cell stain sytox blue (Life Technologies) prior to 
flow cytometric analysis. 
To measure NKCC, the number of lysed K562 target 
cells (defined as sytox blue positive) in a total population 
of 2000 was recorded. From here, the percentage of 
specific cell lysis was calculated as: (TL-SL/2000) × 100, 
where TL is the number of lysed target cells in NK-K562 
co-culture samples and SL is the number of K562 cells 
that underwent lysis when cultured with media alone. To 
measure the target cell–NK cell conjugate formation rate, 
conjugates were defined as K562 cells exhibiting positive 
PE fluorescence and the number in a population of 2000 
K562 cells was recorded.
Statistical analysis 
Statistical analyses were performed using GraphPad Prism 
software (GraphPad Software Ltd) and JMP software, 
version 10 (SAS Institute Inc., Cary, NC, USA). Continuous 
data are summarized as mean and standard deviation (s.d.) 
or median and ranges, depending on whether or not they 
were normally distributed, whereas categorical data are 
summarized as number (%). Associations between AI and 
subject characteristics were assessed using the Kruskal–
Wallis test for continuous variables and the chi-square test 
for categorical variables. Data distribution was examined 
using the Kolmogorov–Smirnov test. For data that 
followed a normal distribution, unpaired Student t tests 
were performed, whereas for non-normally distributed 
data, a Mann–Whitney U test was used. In dot plots, 
horizontal lines represent the median value. Statistical 
significance was accepted at P ≤ 0.05.
Results
Clinical phenotype and demographics in PAI patients 
and controls
We recruited 43 PAI patients (35 females, 8 males) with 
a median age of 49 (range: 18–79)  years (men: 46.5 
(18–64)  years; women: 49 (19–79)  years) (for details 
see Table  1). Median BMI was 23.5 (19–30) kg/m2 in 
the male patients and 25 (19–41) kg/m2 in the women 
with PAI. Steroid replacement therapy consisted of 
hydrocortisone (median daily dose 25 (range: 10–40) mg) 
and fludrocortisone (daily dose 100 (50–300) µg). Most 
patients were taking hydrocortisone in two separate daily 
doses (27/43; 63%), with the remainder taking once-daily 
(3/43; 7%) or thrice-daily doses (13/43; 30%). Eleven of the 
35 women with PAI were on long-standing replacement 
with the androgen precursor DHEA (daily dose: 25 (25–
50) mg), and intake was confirmed by circulating serum 
DHEAS (women without DHEA replacement 0.2 (0.1–
0.2) µmol/L vs 6.7 (3.2–8.3) µmol/L in women on DHEA 
replacement; P < 0.0001).
Underlying cause of disease in the PAI patients was 
autoimmune adrenalitis (n = 37; 15 patients with isolated 
autoimmune Addison’s disease, 22 with autoimmune 
polyglandular syndrome type 2, APS2), permanent 
glucocorticoid deficiency after adrenalectomy for Cushing 
syndrome in one patient and bilateral adrenalectomy in 
the five remaining patients. Duration of PAI since diagnosis 
was established for the first time was 13 (0.5–49)  years. 
Comorbidities in the 22 patients with APS2 included 
autoimmune thyroid disease (n = 18), pernicious anemia 
(n = 3), premature ovarian failure (n = 4), type 1 diabetes 
(n = 2), vitiligo (n = 2) and asthma (n = 2). All APS2 patients 
had a family history of autoimmunity comprising thyroid 
disease (n = 18), ulcerative colitis/Crohn’s disease (n = 5), 
type 1 diabetes mellitus (n = 4), vitiligo (n = 3), PAI (n = 2) 
and pernicious anemia (n = 1). 
We recruited 27 healthy controls, 12 men with a 
median age of 41 (31–61)  years and 15 women aged 
42 (34–50)  years. In addition, we recruited 31 patients 
from the Birmingham 1000 Elders cohort http://www.
birmingham.ac.uk/research/activity/mds/centres/
healthy-ageing/elders.aspx as healthy elderly controls 
(age: 73 (62–91) years).
Neutrophil function in PAI is normal
ROS generation and phagocytosis are two key microbicidal 
mechanisms of neutrophils. When challenged with 
immunoglobulin (Ig) and complement-coated E. coli, 
no difference was found in ROS generation between 
neutrophils from PAI patients and age- and sex-matched 
healthy controls (Table  2). However, a trend (P = 0.07) 
toward a reduced phagocytic index for neutrophils 
from PAI patients was observed (Table  2). A measure of 
phagocytic activity, phagocytic index, takes into account 
both the percentage of neutrophils that have ingested 
bacteria as well as their individual phagocytic activity 
(number of bacteria per cell). Analysis of the phagocytic 
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activity revealed a trend (P = 0.08) toward reduced 
phagocytic activity of neutrophils from PAI patients, 
with no difference found in respect to the percentage of 
neutrophils capable of ingesting E.coli (Table 2).
Surface expression of the FC receptor CD16 is critical 
for neutrophils to phagocytose Ig-coated pathogens. 
Thus, having observed a trend for impaired phagocytosis 
by neutrophils from PAI patients, we compared surface 
expression of CD16 on neutrophils isolated from patients 
and healthy sex- and age-matched controls, which, 
however, revealed no difference between PAI patients and 
controls (Table 2).
Natural killer cell cytotoxicity is decreased in PAI
NK cells rapidly eliminate virally infected cells via 
contact-dependent cytotoxicity, which begins with 
conjugate formation between NK cells and the infected 
Table 1  Clinical characteristics of the 43 patients with primary adrenal insufficiency included in this study.
 
 
 
Patient 
number
 
 
 
Sex  
(F/M)
 
 
 
Age 
(years)
 
 
Body mass 
index  
(kg/m2)
 
Hydro-
cortisone 
daily dose 
(mg)
Number 
of daily 
hydro-
cortisone 
doses
 
 
Fludro-cortisone 
once daily dose 
(g)
 
 
DHEA 
once daily 
dose (mg)
 
 
Duration 
of disease 
(years)
 
 
 
Cause of primary adrenal 
insufficiency
1 F 19 28.3 20 3 150 – 3 Polyglandular syndrome type 2
2 F 20 19.0 20 2 150 – 4 Polyglandular syndrome type 2
3 F 28 32.3 20 2 200 25 9 Polyglandular syndrome type 2
4 F 30 34.5 25 2 100 – 11 Isolated Addison’s disease
5 F 35 21.2 25 2 100 – 12 Isolated Addison’s disease
6 F 35 23.0 25 2 200 25 11 Isolated Addison’s disease
7 F 36 26.5 30 2 250 – 23 Isolated Addison’s disease
8 F 40 21.9 20 2 150 – 17 Polyglandular syndrome type 2
9 F 40 29.0 25 2 150 37.5 5 Polyglandular syndrome type 2
10 F 40 37.2 20 2 300 – 27 Isolated Addison’s disease
11 F 42 22.1 25 2 125 – 11 Polyglandular syndrome type 2
12 F 42 41.0 20 1  – 13 Isolated Addison’s disease
13 F 44 35.0 40 3 100 – 1 Isolated Addison’s disease
14 F 45 23.3 15 2 50 50 14 Polyglandular syndrome type 2
15 F 46 22.9 30 2 100 – 3 Polyglandular syndrome type 2
16 F 48 23.0 25 3 100 – 20 Polyglandular syndrome type 2
17 F 49 20.3 25 2 150 – 26 Polyglandular syndrome type 2
18 F 53 23.0 20 3 100 25 12 Isolated Addison’s disease
19 F 54 27.4 30 2 50 25 17 Polyglandular syndrome type 2
20 F 55 23.0 20 2 100 25 13 Polyglandular syndrome type 2
21 F 56 21.0 30 2 200 – 11 Isolated Addison’s disease
22 F 56 29.4 22.5 3 250 – 30 Polyglandular syndrome type 2
23 F 60 21.2 25 3 100 37.5 12 Polyglandular syndrome type 2
24 F 63 24.7 10 1 100 – 28 Polyglandular syndrome type 2
25 F 63 21.0 15 2 50 – 18 Polyglandular syndrome type 2
26 F 67 29.3 20 2 100 25 30 Polyglandular syndrome type 2
27 F 69 24.4 30 2 100 – 49 Isolated Addison’s disease
28 F 71 25.3 20 1 100 – 31 Polyglandular syndrome type 2
29 F 73 25.0 20 3  – 3 Polyglandular syndrome type 2
30 F 77 26.6 20 3 100 – 24 Polyglandular syndrome type 2
31 F 79 28.0 30 3 50 – 38 Isolated Addison’s disease
32 F 43 18.8 30 2 250 25 1 Bilateral adrenalectomy
33 F 49 25.0 25 2 150 – 7 Bilateral adrenalectomy
34 F 64 25.0 20 3 100 – 12 Bilateral adrenalectomy
35 F 55 31.7 20 2 – 50 27 Adrenalectomy for Cushing 
36 M 18 22.1 25 3 150 – 1 Isolated Addison’s disease
37 M 19 19.4 25 2 100 – 1 Polyglandular syndrome type 2
38 M 38 23.0 40 3 150 – 14 Isolated Addison’s disease
39 M 59 20.6 30 3 150 – 8 Polyglandular syndrome type 2
40 M 63 28.0 30 2 100 – 29 Isolated Addison’s disease
41 M 64 30.0 30 2 150 – 29 Isolated Addison’s disease
42 M 30 24.0 30 2 300 – 6 Bilateral adrenalectomy
43 M 55 28.2 25 2 100 – 4 Bilateral adrenalectomy
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target cell. Through the use of two-color flow cytometry, 
we performed a simultaneous assessment of conjugate 
formation and natural killer cell cytotoxicity (NKCC). 
NK cells from PAI patients exhibited significantly reduced 
cytotoxicity toward transformed cells when compared 
to NK cells from healthy controls (PAI: 12.0 ± 1.5% vs 
21.1 ± 2.6% in controls, P < 0.0001) (Fig.  1A), whereas 
both groups exhibited similar ability for NK cell–target 
cell conjugate formation (Fig. 1B). 
Natural killer granzyme B expression is  
increased in PAI
Granule exocytosis is the predominant mechanism by 
which NK cells mediate target cell lysis. Two molecules 
central to this form of NK cell defense are the pore-forming 
protein perforin and the serine protease granzyme B. 
We found no difference in the percentage of perforin or 
granzyme B-positive NK cells between PAI patients and 
their age- and sex-matched controls (Fig.  2A and B). 
Similarly, no differences were observed in the staining 
intensity (median fluorescence intensity) of perforin 
between PAI and controls (59.9 ± 36.4 vs 47.0 ± 28.7; 
P = 0.12) (Fig. 2C and E). However, the staining intensity 
of granzyme B was found to be significantly higher in NK 
cells from PAI patients than that in controls (21.1 ± 11.1 vs 
14.5 ± 7.5; P = 0.007) (Fig. 2D and F).
Natural killer cell-activating receptor expression is 
decreased in PAI
The induction of NKCC is governed in part by signals 
transmitted through surface-expressed NK cell-activating 
receptors, which recognize ligands present on the surface 
of target cells. To determine whether altered NK cell-
activating receptor expression could explain the impaired 
NKCC in PAI patients, we measured the surface expression 
of the NK cell-activating receptor NKG2D and the natural 
cytotoxicity receptors NKp30 and NKp46. Compared to 
healthy controls, the percentage of NK cells expressing 
NKG2D and NKp46 was significantly lower in PAI patients 
as was the surface density of NKG2D (all P < 0.0001). In 
addition, a trend (P = 0.06) for a reduced frequency of 
NKp30-positive NK cells was observed (Table 3). 
Discussion
Although infections are a common occurrence among 
patients with PAI (3, 9, 10) and a major cause of the excess 
mortality that is observed among this patient group (6, 7), 
it is currently unknown as to why these individuals 
report more frequent and severe infectious episodes when 
compared to the general population. Here, we have carried 
Table 2 Neutrophil phagocytosis, reactive oxygen species (ROS) generation and surface CD16 expression in 42 PAI patients and 
27 healthy, sex- and age-matched controls. For the assessment of CD16 expression, 41 PAI patients and 27 healthy controls were 
studied. Values are presented as mean ± standard deviation.
  PAI patients Healthy controls P
Phagocytic index 257 252 ± 87 162 299 220 ± 98 779 0.07
% Phagocytosing neutrophils 98.0 ± 1.5 98.2 ± 1.2 0.68
Phagocytic activity (MFI) 262 469 ± 88 707 304 941 ± 100 876 0.08
ROS generation (MFI) 57 023 ± 26 463 49 915 ± 19 302 0.23
% CD16+ neutrophils 97.46 ± 1.82 96.63 ± 3.04 0.33
CD16 surface density 58 775 ± 27 559 68 380 ± 31 401 0.20
MFI, median fluorescence intensity. Phagocytic index calculated as (% phagocytosis/100) × phagocytic activity.
Figure 1
Natural killer cell cytotoxicity and conjugate formation. Panel 
A, cytotoxicity of resting NK cells isolated from PAI patients 
(n = 41) and age- and sex-matched healthy controls (n = 29) 
toward the erythroleukemic K562 cell line at an 
effector:target cell ratio of 10:1. Horizontal line depicts the 
median value. Panel B, percentage of NK cells bound to K562 
tumor cells as a measure of conjugate formation between 
effector (NK) and target (K562) cells. Conjugate formation was 
assessed following a 4-h co-culture at an effector:target cell 
ratio of 10:1. Data were obtained from 41 PAI patients and 28 
age- and sex-matched healthy controls. Horizontal line depicts 
the median value.
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out a comparative assessment of the function and surface 
phenotype of NK cells and neutrophils isolated from PAI 
patients and age- and sex-matched healthy controls in an 
effort to ascertain whether defects in innate immunity 
could explain the increased susceptibility of PAI patients 
to infection. 
 As the first immune cell to arrive at a site of infection, 
neutrophils provide immediate frontline protection 
against rapidly dividing bacteria, fungi and yeast. Based 
on the results of a recent study that reported an increased 
incidence of fungal infection in PAI patients (10), we 
hypothesized that neutrophils from these patients would 
exhibit impaired microbicidal activity when compared to 
healthy controls. Although no difference was found in 
ROS generation between the two groups, we observed a 
trend (P = 0.07) toward reduced phagocytosis of opsonized 
E.coli by neutrophils from PAI patients, an impairment 
that could negatively influence their ability to eliminate 
invading pathogens, though clearly this would appear not 
to be a major contributor to the increased incidence of 
infection among this group. 
In contrast, we have shown for the first time that NK 
cells isolated from patients with PAI exhibit significantly 
impaired cytotoxicity at the single cell level. As NK cells 
are involved in the early recognition and elimination of 
virus-infected cells, this defect in NKCC may be one factor 
underlying the increased incidence and severity of viral 
infections reported by PAI patients (10). Interestingly, 
a recent report has described reduced innate anti-viral 
responses in PBMCs in PAI, specifically reduced CXCL9 
and CXCL10 production in response to stimulation with 
interferon (14). Taking those findings together with our 
data, we are now looking at significant evidence that there 
is a major defect in the innate immune response in PAI, 
potentially increasing susceptibility to viral infections.
The adrenal androgen precursor dehydro-
epiandrosterone (DHEA) has been reported to increase 
NK cell numbers (15, 16), albeit mainly in rodent-based 
studies, which complicates matters as rodent adrenals do 
not produce DHEA in substantial amounts. One human-
based study has examined the immunological effects 
of twelve-week dehydroepiandrosterone replacement 
therapy in patients with PAI (17) and found that DHEA 
treatment reduced the frequency of NK and NKT cells. 
However, the study did not comment on baseline 
differences in NK cell function or frequency between 
patients and healthy controls. In our studies, we found 
no difference in circulating NK cell numbers between PAI 
patients and healthy controls, but found significantly 
decreased NKCC, which was equally reduced in patients 
with and without long-standing DHEA replacement 
therapy (Fig.  3A), excluding DHEA deficiency as the 
causative factor explaining the observed decrease 
in NKCC.
Glucocorticoids have been shown to potently 
suppress NKCC in a series of in vitro studies (18, 19, 20). 
Figure 2
Intracellular perforin and granzyme B expression in resting NK 
cells. Panels A and C, NK cells isolated from PAI patients 
(n = 42) and age- and sex-matched healthy controls (n = 34) 
were analyzed for intracellular perforin expression. Data are 
presented as percentage positive NK cells (Panel A) and 
staining intensity (Panel C). Horizontal line depicts the median 
value. Panels B and D, NK cells isolated from PAI patients 
(n = 39) and age- and sex-matched healthy controls (n = 30) 
were analyzed for intracellular granzyme B expression. 
Data are presented as percentage positive NK cells (Panel B) 
and staining intensity (Panel D). Horizontal line depicts the 
median value. MFI, mean fluorescence intensity. Panels E and 
F, representative flow cytometry plots depicting intracellular 
perforin (Panel E) and granzyme B (Panel F) expression in NK 
cells isolated from a single PAI patient (blue line) and  
healthy control (red line). The black line represents the  
isotype control.
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Current  glucocorticoid replacement options are not able 
to mimic the physiologic circadian cortisol secretion 
but result in non-physiological peak and trough cortisol 
concentrations equating to transient over- and under-
replacement, which could impact on NK cell function 
through altered CLOCK gene regulation of immune 
function. NK cells of mice with deletion of the clock gene 
period circadian clock 1 (Per1) display significantly altered 
diurnal rhythms of cytokine release and expression of the 
cytolytic factors perforin and granzyme B (21). This resonates 
with our finding of increased granzyme B expression in the 
NK cells of our PAI patients. Moreover, in a recent paper, 
it has been shown that oral hydrocortisone in doses of 
20 mg acutely upregulate PER1 in human peripheral blood 
mononuclear cells and that glucocorticoid pulses can be 
used to entrain an aberrant diurnal rhythm (22).
The induction of NKCC is governed in part by signals 
transmitted through surface-expressed germline-encoded 
activatory receptors (23). Upon ligand recognition, NK 
cell-activating receptors, which include the natural 
cytotoxicity receptors NKp30 and NKp46 and the C-type 
lectin family member NKG2D, initiate diverse signaling 
pathways, which provided they overcome signals from 
inhibitory receptors lead to NK cell activation (24). 
For the cytotoxicity assays performed in this study, 
the MHC class I-deficient erythroleukemic K562 cell 
line was used as the target cell. Signaling through the 
NK cell-activating receptor NKG2D has been shown to 
be primarily responsible for NK-mediated lysis of K562 
cells (25). Compared to healthy controls, we found that 
both the frequency of NKG2D-positive NK cells and its 
surface density were significantly lower in PAI patients, 
highlighting a potential mechanistic explanation for 
the reduced cytotoxicity of NK cells from PAI patients 
against K562 cells. In addition to NKG2D, we found a 
significantly reduced frequency of circulating NKp46-
positive NK cells among PAI patients and a trend (P = 0.06) 
for a reduced percentage of NKp30-positive NK cells. 
Although changes in NKp46 and NKp30 expression are 
unlikely to be responsible for the impaired cytotoxicity 
against K562 cells we have described in this report (25), 
they may contribute to the increased susceptibility 
of PAI patients to infection. For example, NKp46 has 
been shown to directly bind the hemagglutinin of 
influenza virus (26) and to detect human monocytes 
infected with mycobacterium tuberculosis (TB) (27). 
Thus, a reduced frequency of NK cells expressing NKp46 
may explain to some degree the increased incidence 
of viral infections among PAI patients (10) and may 
also hamper the immune response against TB, which 
represents a major cause of PAI disease in the developing 
world. In respect of NKp30, this receptor has been 
shown to play an essential role in NK cell-dependent 
maturation of dendritic cells (DCs) (28), a professional 
Table 3 Expression of activatory surface receptors on the surface of natural killer (NK) cells. For NKG2D, NK cells isolated from 
42 PAI patients and 30 healthy controls were studied. For NKp30, n = 40 for PAI patients and n = 30 for healthy controls. 
For NKp46, we studied NK cells from 42 PAI patients and 32 healthy controls. Values are presented as mean ± standard deviation. 
Significant differences are indicated in bold font.
 Percentage positive NK cells Surface density (MFI)  
 Healthy controls PAI patients P Healthy controls PAI patients P
NKG2D 92.6 ± 4.3 78.0 ± 11.9 <0.0001 34.8 ± 7.9 20.4 ± 5.8 <0.0001
NKp30 65.6 ± 20.5 56.4 ± 19.6 0.06 14.5 ± 8.8 13.6 ± 8.0 0.34
NKp46 46.8 ± 212 27.9 ± 14.0 <0.0001 7.6 ± 4.0 6.7 ± 2.9 0.32
MFI, mean fluorescence intensity.
Figure 3
Natural killer cell cytotoxicity (NKCC), DHEA replacement 
therapy and cause of primary adrenal insufficiency (PAI). 
Panel A shows NKCC (median and individual data points) as 
assessed in healthy controls (n = 29) and patients with PAI 
(n = 41), separated into patients with (n = 11) and without 
(n = 30) chronic DHEA replacement therapy. Panel B shows 
NKCC (median and individual data points) in healthy controls 
(n = 29), patients with PAI due to autoimmune adrenalitis 
(n = 36) and patients with PAI after bilateral adrenalectomy 
(n = 4). Statistical comparisons were made with a non-
parametric Kruskal–Wallis test with Dunn’s multiple 
comparison test. *P < 0.05; **P < 0.01; ***P < 0.001.
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antigen-presenting cell that promotes the initiation of 
an adaptive immune response. Thus, it is conceivable 
that as a consequence of decreased NKp30 expression, 
the process of NK-dependent DC maturation would be 
impaired in PAI patients, hampering the development 
of an antigen-specific adaptive immune response, one 
consequence of which would be delayed clearance of 
invading pathogens. 
One potential explanation for the downregulation 
of activatory receptors on NK cells from PAI patients is 
a change in epigenetic regulation. In a recent study, 
Bjanesoy  et  al. (29) identified multiple hypomethylated 
gene promoter regions in CD4+ T cells isolated from 
PAI patients. Given that in vitro treatment of NK cells 
with demethylating agents has been shown to result in 
decreased surface expression of NKG2D (30), it would 
be of interest for future studies to examine the DNA 
methylation profile of NK cells from PAI patients, focusing 
primarily upon the promoters of genes that encode NK 
cell activatory receptors. 
Of note, the polymorphic MHC class I polypeptide-
related sequence A (MICA) molecule is a ligand for 
NKG2D and one of its variants, MICA5.1 or ICA*008, 
has been shown to be strongly associated with the risk 
of developing autoimmune Addison’s disease (31). This 
would suggest that the low NKCC we observed in our 
PAI patient cohort may be more related to the cause than 
to the consequences of PAI. However, we also included 
patients with PAI due to bilateral adrenalectomy, i.e., 
patients with no underlying autoimmune disorder, and 
this patient group, albeit small in size, showed similar 
and significant decreases in NKCC (Fig.  3B) and also 
NKG2D expression.
Taken together, we have shown for the first time 
that NKCC is significantly decreased in patients with 
PAI, providing a potential causal link explaining 
increased morbidity and mortality in PAI patients as 
a consequence of respiratory infections. Neither cause 
of disease nor DHEA replacement did influence the 
significant reduction in NKCC in PAI patients, which 
leads us to propose that the lack of diurnal cortisol 
delivery and consequently altered peripheral CLOCK 
gene regulation of immune cells may be the underlying 
causative mechanism. It will be highly interesting 
to examine whether introduction of glucocorticoid 
replacement with a delivery mode mimicking the 
physiological diurnal profile including the early morning 
cortisol surge (32, 33) could reestablish normal NKCC in 
adrenal insufficiency and help to reduce morbidity and 
ultimately mortality.
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